Merrill maintains Keryx at buy

Keryx Biopharmaceuticals Inc. was maintained at a buy rating by Merrill Lynch analyst Thomas McGahren. The company reported a fourth-quarter 2005 loss per share of $0.24, wider than Merrill's estimate of loss per share of $0.20. The analyst widened his estimated loss per share in 2006 to $1.03 from $0.82. Keryx is one of Merrill's top small cap biotech picks for 2006. Shares of the New York City pharmaceutical company were down 14 cents, or 0.80%, at $17.46 on volume of 482,396 shares versus the three-month running average of 372,877 shares. (Nasdaq: KERX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.